Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 25 2024 - 4:30PM
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, today announced that
Chairman and CEO Shane J. Schaffer, PharmD, and preeminent
board-certified psychiatrist and Cingulate scientific advisor Dr.
Ann Childress, MD, will participate in a live Benzinga All Access
event on June 26, 2024, at 10:30 a.m. CST.
The discussion will address the current unmet needs in Attention
Deficit/Hyperactivity Disorder (ADHD), a review of the results from
Cingulate’s Phase 3 Fixed-Dose Study in pediatrics and adolescents,
and the potential expansion of Cingulate’s PTR platform into other
therapeutic areas. Dr. Schaffer will also provide a company
overview.
The event may be viewed live on Benzinga’s YouTube
channel, Benzinga All Access, and will also
be available for viewing on Cingulate’s website
at cingulate.com/investors.
About
Cingulate® Cingulate Inc. (NASDAQ:
CING), is a clinical-stage biopharmaceutical company utilizing its
proprietary Precision Timed Release™ (PTR™) drug delivery platform
technology to build and advance a pipeline of next-generation
pharmaceutical products, designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by
burdensome daily dosing regimens and suboptimal treatment outcomes.
With an initial focus on the treatment of Attention
Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and
evaluating additional therapeutic areas where PTR technology may be
employed to develop future product candidates, including to treat
anxiety disorders.Cingulate is headquartered in Kansas City. For
more information visit Cingulate.com
About Dr. Ann Childress, MDAnn C. Childress,
M.D., a board-certified physician in Psychiatry and Neurology,
specializing in child, adolescent, and adult psychiatry, has been a
practicing psychiatrist for more than 35 years. Dr. Childress has
held numerous prominent positions, including chief of mental health
at various psychiatric hospitals as well as professorships within
prestigious universities. Dr. Childress is President of the
American Professional Society of ADHD and Related Disorders,
Education Director for the Nevada Psychiatric Association, a
distinguished life fellow of the American Psychiatric Association
and a member of the American Academy of Child and Adolescent
Psychiatry.
Dr. Childress is the founder and principal investigator of
Clinical Research of Southern Nevada and is the founder and
president of the Center for Psychiatry and Behavioral Medicine,
both entities located in Las Vegas, Nevada. She has conducted more
than 180 clinical studies, working on most of the major psychiatric
drugs that have been approved over the last few decades by various
major pharmaceutical companies, including Pfizer, Janssen, Shire,
AstraZeneca, and Novartis.
Dr. Childress has been working with Cingulate since 2018,
serving as a key opinion and thought leader, helping design
multiple clinical protocols, and served as the lead investigator on
Cingulate’s Phase 3 Fixed-Dose Study in pediatrics and
adolescents.
Investor Relations Thomas Dalton Head
of Investor & Public Relations,
CingulateTDalton@cingulate.com 913-942-2301
Matt KrepsDarrow
Associatesmkreps@darrowir.com 214-597-8200
Cingulate (NASDAQ:CINGW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cingulate (NASDAQ:CINGW)
Historical Stock Chart
From Oct 2023 to Oct 2024